ACE inhibitors: future perspectives
Reid, J.L.
Journal of Cardiovascular Pharmacology 22(Suppl 1): S41-S43
1993
ISSN/ISBN: 0160-2446 PMID: 7507539 Document Number: 412424
There are chemical differences among angiotensin-converting enzyme (ACE) inhibitors that profoundly influence the pharmacokinetics and dynamics of different drugs. Differences in potency, affinity, and duration of action can be readily identified. These factors, together with individual binding characteristics of drug (or metabolite) to ACE, may influence the profile of hemodynamics and adverse effects, including first-dose hypotension and renal impairment. Differential inhibition of ACE in tissues (e.g., heart, brain, adrenal, kidney, blood vessel) could be important in identifying a particular ACE inhibitor for a specific clinical indication.